Advertisement

Topics

PEG-3350 & ELECTROLYTES FOR ORAL SOLUTIONRx Only | PEG-3350 and Electrolytes [Lannett Company, Inc..] | BioPortfolio

13:35 EST 27th January 2019 | BioPortfolio

Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

PEG-3350 & ELECTROLYTES is a colon lavage preparation provided as water-soluble components for solution. In solution each PEG-3350 & ELECTROLYTES preparation delivers the following, in grams per liter.

When dissolved in sufficient water to make 4 liters, the final solution contains 125 mEq/L sodium, 10 mEq/L potassium, 20 mEq/L bicarbonate, 80 mEq/L sulfate, 35 mEq/L chloride and 18 mEq/L polyethylene glycol 3350. The reconstituted solution is isosmotic and has a mildly salty taste. PEG-3350 & ELECTROLYTES is administered orally or via nasogastric tube.

 Polyethylene glycol 3350  60.00
 Sodium chloride  1.46
 Potassium chloride  0.745
 Sodium bicarbonate  1.68
 Sodium sulfate  5.68

PEG-3350 & ELECTROLYTES cleanses the bowel by induction of diarrhea. The osmotic activity of polyethylene glycol 3350, in combination with the electrolyte concentration, results in virtually no net absorption or excretion of ions or water. Accordingly, large volumes may be administered without significant changes in fluid and electrolyte balance.

PEG-3350 & ELECTROLYTES is indicated for bowel cleansing prior to colonoscopy or barium enema X-ray examination.

PEG-3350 & ELECTROLYTES is contraindicated in patients known to be hypersensitive to any of the components. PEG-3350 & ELECTROLYTES is contraindicated in patients with ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis or toxic megacolon.

No additional ingredients (e.g., flavorings) should be added to the solution. PEG-3350 & ELECTROLYTES should be used with caution in patients with severe ulcerative colitis.

Patients with impaired gag reflex, unconscious or semiconscious patients and patients prone to regurgitation or aspiration should be observed during the administration of PEG-3350 & ELECTROLYTES, especially if it is administered via nasogastric tube.

If gastrointestinal obstruction or perforation is suspected appropriate studies should be performed to rule out these conditions before administration of PEG-3350 & ELECTROLYTES.

PEG-3350 & ELECTROLYTES produces a watery stool which cleanses the bowel prior to examination.

For best results, no solid food should be ingested during the 3 – 4 hour period prior to the initiation of PEG-3350 & ELECTROLYTES administration. In no case should solid foods be eaten within 2 hours of drinking PEG-3350 & ELECTROLYTES.

The rate of administration is 240 mL (8 fl. oz.) every 10 minutes. Rapid drinking of each portion is preferred rather than drinking small amounts continuously.

The first bowel movement should occur approximately one hour after the start of PEG-3350 & ELECTROLYTES administration.

Administration of PEG-3350 & ELECTROLYTES should be continued until the watery stool is clear and free of solid matter. This normally requires the consumption of approximately 3–4 liters (3–4 quarts), although more or less may be required in some patients. The unused portion should be discarded.

Oral medication administered within one hour of the start of administration of PEG-3350 & ELECTROLYTES may be flushed from the gastrointestinal tract and not absorbed.

Studies to evaluate carcinogenic or mutagenic potential or potential to adversely affect male or female fertility have not been performed.

Animal reproduction studies have not been conducted with PEG-3350 & ELECTROLYTES, and it is not known whether PEG-3350 & ELECTROLYTES can affect reproductive capacity or harm the fetus when administered to a pregnant patient. PEG-3350 & ELECTROLYTES should be given to a pregnant patient only if clearly needed.

Safety and effectiveness in pediatric patients have not been established.

Published literature contains isolated reports of serious adverse reactions following the administration of PEG-ELS products in patients over 60 years of age. These adverse events include upper GI bleeding from Mallory-Weiss Tear, esophageal perforation, asystole, sudden dyspnea with pulmonary edema, and "butterfly-like" infiltrate on chest x-ray after vomiting and aspirating PEG.

Nausea, abdominal fullness and bloating are the most frequent adverse reactions, occurring in up to 50% of patients. Abdominal cramps, vomiting and anal irritation occur less frequently. These adverse reactions are transient. Isolated cases of urticaria, rhinorrhea, dermatitis, and rarely anaphylaxis, angioedema, tongue edema, and face edema have been reported which may represent allergic reactions.

PEG-3350 & ELECTROLYTES can be administered orally or by nasogastric tube. Patients should fast at least 3 hours prior to administration. A one hour waiting period after the appearance of clear liquid stool should be allowed prior to examination to complete bowel evacuation. No foods except clear liquids should be permitted prior to examination after PEG-3350 & ELECTROLYTES administration.

The recommended adult oral dose is 240 mL (8 fl. oz.) every 10 minutes (see INFORMATION FOR PATIENTS). Lavage is complete when fecal discharge is clear. Lavage is usually complete after the ingestion of 3–4 liters.

PEG-3350 & ELECTROLYTES is administered at a rate of

20-30 mL per minute (1.2-1.8 L/hour).

4 Liter: Add tap water to FILL line. Replace cap tightly and mix or shake well until all ingredients have dissolved. (No additional ingredients, e.g. flavorings, should be added to the solution.)

PEG-3350 & ELECTROLYTES is supplied in 4 liter bottles. Each 4 liter bottle contains polyethylene glycol 3350 240 g, sodium chloride 5.84 g, potassium chloride 2.98 g, sodium bicarbonate 6.72 g, sodium sulfate (anhydrous) 22.72 g. The preparation is supplied in powdered form for oral administration as a solution.

PEG-3350 & ELECTROLYTES 4 liter NDC 62175-446-01

Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F).

KEEP RECONSTITUTED SOLUTION REFRIGERATED. USE WITHIN 48 HOURS. DISCARD UNUSED PORTION.

Distributed by:

Kremers Urban Pharmaceuticals Inc.

Princeton, NJ 08540, USA

L2152J Rev. 3E 01/2011

1.To make PEG-3350 & ELECTROLYTES solution, add tap water to the top of the FILL line marked 4 liters. Replace cap tightly and mix or shake well until ingredients have dissolved. (No additional ingredients should be added to the solution.)

2.Refrigerate the solution until ready to drink. Chilling improves the taste. Store no longer than 48 hours.

3.For best results, solid food should not be eaten during the 3 – 4 hour period before you start drinking the solution. Never eat solid food within 2 hours of drinking the solution.

4.Drink a large glassful (8 fl. oz.) of PEG-3350 & ELECTROLYTES every 10 minutes. It is best to drink the PEG-3350 & ELECTROLYTES rapidly, rather than sipping slowly. Continue drinking a glassful every 10 minutes until your watery stool is clear and free of solid matter. This normally requires drinking approximately 3 – 4 liters (3 – 4 quarts). Using the bottle marks as a guide this means either the entire bottle should be empty (4 liters consumed), or the solution should be at or below the 1 liter mark (at least 3 liters consumed).

KEEP RECONSTITUTED SOLUTION REFRIGERATED.

USE WITHIN 48 HOURS. DISCARD UNUSED PORTION.

DATE RECONSTITUTED: _____________TIME RECONSTITUTED: ____________

PEEL HERE

NDC 62175-446-01

Note to pharmacist: See base label for mixing information. Package insert enclosed. Remove before dispensing.

PEG-3350 & ELECTROLYTES for Oral Solution

Rx Only

L2152J Rev. 3E 01/2011

Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F)

KEEP RECONSTITUTED SOLUTION REFRIGERATED. USE WITHIN 48 HOURS. DISCARD UNUSED PORTION.

APPROXIMATE NET WEIGHT: 278 GRAMS

L2152J

 4 Liters
 This bottle contains the following ingredients:
 Polyethylene glycol 3350  240.00 grams
 Sodium Chloride  5.84 grams
 Potassium Chloride  2.98 grams
 Sodium bicarbonate  6.72 grams
 Sodium sulfate (anhydrous)  22.72 grams
 When dissolved in sufficient water to make 4 liters, the final solution
contains 125 mEq/L sodium, 10 mEq/L potassium, 20 mEq/L
bicarbonate, 80 mEq/L sulfate, 35 mEq/L chloride and 18 mEq/L
polyethylene glycol 3350.

Manufacturer

Lannett Company, Inc..

Active Ingredients

Source

Drugs and Medications [75 Associated Drugs and Medications listed on BioPortfolio]

Benzo-jel [henry schein, inc.]

Benzo-Jel™ Unit Dose

Polyethylene glycol-3350 and electrolytes with flavor pack [novel laboratories, inc.]

PEG-3350 (240 g) and Electrolytes for Oral Solution, USP with flavor pack

Peg-3350 and electrolytes [physicians total care, inc.]

AFFORDABLE PHARMACEUTICALS LLCPEG-3350 and Electrolytes

Polyethylene glycol-3350 and electrolytes [novel laboratories, inc.]

These highlights do not include all the information needed to use PEG-3350 and electrolyte for oral solution safely and effectively. See full prescribing information for PEG-3350 and electrolyte for o...

Polyethylene glycol 3350 [atlantic biologicals corps]

Polyethylene Glycol 3350 NF Polyethylene Glycol 3350 Powder for Oral Solution

Clinical Trials [81 Associated Clinical Trials listed on BioPortfolio]

Comparison of Two Types of Bowel Preparation for Inpatient Colonoscopy

Bowel preparation is a crucial step prior to colonoscopy to help with the optimal assessment of the colonic mucosa. Inadequate bowel preparation increases the length of the procedure, and ...

Preference of Tegaserod vs. PEG 3350 in Patients With Constipation

To determine whether female patients have a preference for tegaserod of PEG 3350 relative to dosage form, convenience, ease of administration and taste

Comparison Trial of Enema vs. PEG 3350 for Constipation

The purpose of this study is to determine if milk and molasses enema or PEG 3350 works better for treatment of fecal impaction in children who are constipated.

Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer

This randomized phase II trial studies how well macrogol 3350-based oral osmotic laxative (polyethylene glycol 3350) works in preventing cancer in patients at risk of colorectal cancer. Ch...

Study Comparing PEG 3350 Laxative to Placebo in the Treatment of Occasional Constipation (Study CL2007-12)(COMPLETED)

Randomized, placebo-controlled, double blind study. 203 subjects entered the study to compare the effect on occasional constipation of polyethylene glycol 3350 to placebo. Subjects took on...

PubMed Articles [195 Associated PubMed Articles listed on BioPortfolio]

Macrogol (polyethylene glycol) 4000 without electrolytes in the symptomatic treatment of chronic constipation: a profile of its use.

Macrogol 4000, a biologically inert, non-absorbable osmotic laxative, is a highly effective and well-tolerated first-line option for the treatment of the symptoms of chronic idiopathic/functional cons...

PEG 3350 Versus Lactulose for Treatment of Functional Constipation in Children: Randomized Study.

The aim of this study was to compare the clinical efficacy and tolerance of polyethylene glycol 3350 (PEG) and lactulose for the treatment of functional constipation in infants and children.

Bowel Preparation for Colonoscopy in Children: 1 Day PEG-3350 with Bisacodyl versus 3 Day Sennosides.

Bowel preparation (BP) for colonoscopy is a challenging procedure in children and different regimens have been used for this purpose. Polyethylene glycol (PEG) is the most preferred agent in recent ye...

Nanohybrid Electrolytes for High Energy Lithium-ion Batteries: Recent Advances and Future Challenges.

Next-generation lithium-ion batteries (LIBs) will have 2~3 times increase in energy density compared to today's technology due to the adoption of new cathode and anode materials. In addition, their sa...

High-Voltage and Low-Temperature Aqueous Supercapacitor Enabled by "Water-in-Imidazolium Chloride" Electrolytes.

Symmetric aqueous high voltage supercapacitors up to 3 V have been demonstrated using concentrated aqueous 1-butyl-3-methylimidazolium chloride (BMImCl), namely, "water-in-imidazolium chloride", as wo...

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Radiology
Radiology is the branch of medicine that studies imaging of the body; X-ray (basic, angiography, barium swallows), ultrasound, MRI, CT and PET. These imaging techniques can be used to diagnose, but also to treat a range of conditions, by allowing visuali...


Drugs and Medication Quicklinks


Searches Linking to this Drug Record